Drug Profile
Research programme: neurological disorders therapeutics - Paradigm Therapeutics/Takeda
Latest Information Update: 13 Feb 2008
Price :
$50
*
At a glance
- Originator Paradigm Therapeutics; Takeda
- Developer Takeda
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued CNS disorders
Most Recent Events
- 30 Jun 2005 Preclinical trials in CNS disorders in Japan (PO)
- 30 Jun 2005 Preclinical trials in CNS disorders in United Kingdom (PO)